Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575252 | 1.00 | POLB (0.47) | POLBKDM4EL3MBTL1CHRM1MAPK1 | |
| SCHEMBL1575304 | 0.99 | POLB (0.45) | POLBKDM4EL3MBTL1CHRM1MAPK1 | |
| SCHEMBL3125309 | 0.84 | CHRM1 (0.50) | POLBKDM4EL3MBTL1CHRM1MAPK1 | |
| SCHEMBL1575439 | 0.81 | KMT2A (0.48) | POLBKDM4EL3MBTL1CHRM1MAPK1 | |
| SCHEMBL1575275 | 0.80 | POLB (0.54) | POLBKDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL1574957 | 0.79 | L3MBTL1 (0.51) | POLBKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1574650 | 0.78 | LMNA (0.55) | KDM4EL3MBTL1CHRM1ALDH1A1MEN1 | |
| SCHEMBL1574560 | 0.78 | LMNA (0.55) | KDM4EL3MBTL1CHRM1ALDH1A1MEN1 | |
| SCHEMBL1575293 | 0.77 | L3MBTL1 (0.55) | POLBL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL1576048 | 0.76 | LMNA (0.52) | KDM4EL3MBTL1CHRM1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | POLB 4641/4885KDM4E 516/4885L3MBTL1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.